Expression of the CD40 ligand (CD40L) on tumors can activate host immune systems and produce antitumor effects against the tumors. To deliver the CD40L gene efficiently, we evaluated the efficiency of transduction of different serotypes of adeno-associated virus (AAV) vectors in lung cancer A549 cells and compared the transduction efficiency of a conventional AAV vector with that of self-complementary AAV (scAAV) vectors as well. We determined that serotype AAV2/5 transduced A549 cells much more efficiently than serotypes AAV2/1, AAV2/2, AAV2/6, AAV2/7, AAV2/8, AAV2/9 and AAV2/10. And the transduction efficiency of scAAV2/5 was significantly higher than conventional AAV2/5. Furthermore, pretreatment with carboplatin, which is a chemotherapeutic agent used in lung cancer chemotherapy, substantially increased AAV-mediated transgene expression. The scAAV2/5 vectors encoding human CD40L were used to tranduce CD40L into A549 cells, which were then co-cultivated with immature human dendritic cells (DCs). Interleukin 12 (IL-12) that was released was measured in the culture supernatant. Specificity of the immunostimulatory effect of CD40L was confirmed by blocking with a monoclonal antibody binding to human CD40L. The in vivo antitumor activity was evaluated in BALB/c nude mice bearing A549 lung cancer. scAAV2/5-CD40L showed significant inhibitory effects on the growth of transplanted tumor cells as compared with control group. These studies suggest that recombinant AAV2/5-CD40L may provide an effective form of therapy for lung cancer.
Introduction
Lung carcinoma is the leading cause of malignancy-related mortality. Non-small cell lung cancer now accounts for about three-quarters of all cases of lung cancer, which is primarily due to a propensity to metastasize as well as resistance to chemotherapy and radiation (Singh and Dhindsa, 2007) . Therefore, supplementing conventional systemic treatment with gene therapy as a new approach to eradicate malignant cells might be beneficial to cancer patients at all stages of the disease.
Transduction of a therapeutic transgene may induce a persistent immune response to molecular characteristics of the malignant phenotype. The most potent immunotherapeutic approaches aim at the generation of tumor antigen-specific cytotoxic T-lymphocytes (CTLs) (Pardoll and Allison, 2004) .
Such immune responses require cross presentation of tumor antigens by activated antigen-presenting cells (APCs), e.g. dendritic cells (DCs) (Albert et al., 2001) . To achieve activation of naive tumor-specific CTLs, DCs have to undergo a maturation process dependent on stimulation of CD40 by the CD40 ligand (CD40L). Therefore, transduction of CD40L will be helpful in the immunotherapy of tumor, such as lung carcinoma.
Actually, the concept of treating human diseases by introducing normal alleles of genes into appropriate target cells has become a clinical reality. Although a variety of physical and chemical methods have been developed for introducing exogenous DNA sequences into eukaryotic cells, viruses have generally been proven to be much more efficient for this purpose. Adeno-associated virus (AAV), a nonpathogenic human parvovirus, has gained attention as a potentially safe vector for gene transfer and gene therapy.
In the current study, we explore the most efficient serotype of AAV in lung cancer A549 cells, and the potential effect of co- 
Results

Transduction efficiency of different serotypes of AAV in A549 cells
AAV vectors transduce certain cell types, such as brain and muscle, exceedingly well; however, controversies exist with reference to their transduction efficiency in the lung. AAV2-mediated cystic fibrosis transmembrane regulator (CFTR) gene transfer into the human cystic fibrosis lung has been extensively studied in clinical trials. However, CFTR gene expression in these trials was sufficiently low to preclude the detection of transgene-derived CFTR mRNA. AAV serotype 2 is the first primate AAV to be cloned and the most extensively studied. Recently, the identification of optimal AAV serotypes for a given tissue target has been an area of intense interest in gene therapy research. As we know, the availability of several additional AAV serotype vectors, such as AAV1 through AAV10, has attracted further attention; and their potential use as vectors in human gene therapy is imminent (Grimm and Kay, 2003; VirellaLowell et al., 2005; Yan et al., 2000) .
Transduction efficiency of AAV in A549 cells has not been widely known. In our studies, the transduction efficiency of the serotypes AAV2/1, AAV2/2, AAV2/5, AAV2/6, AAV2/7, AAV2/8, AAV2/9 and AAV2/10 expressing green fluorescent protein (GFP) in A549 cells was evaluated. A549 cells were infected with different serotype AAV vectors at MOI of 10 4 particles/cell, the transduction efficiency was measured at 48 h post-infection. As shown in Fig. 1 , compared to serotypes AAV2/1, AAV2/2, AAV2/6, AAV2/7, AAV2/8, AAV2/9 and AAV2/10, AAV2/5-mediated transgene expression was the highest, which is consistent with Shi's report (Shi et al., 2005) . However, the transduction efficiency of all these serotypes including the AAV2/5 was still low.
Transduction efficiency of scAAV2/5 in A549 cells Shi et al. have reported that the transduction rate was ∼70% in A549 when they were infected with AAV2/5. Our studies suggested it was less than 20%. However, in Shi's studies, the cells were infected at a very high MOI, which was 5 × 10 4 . Such a high MOI is infeasible in a clinical trial.
As we know, the AAV genome is a single-stranded DNA (Berns and Giraud, 1996; Muzyczka, 1992) , which is transcriptionally inactive. Previous studies have suggested that viral second-strand DNA synthesis is the rate-limiting step in AAVmediated transgene expression (Ferrari et al., 1996; Fisher et al., 1996; Mah et al., 1998; Zhong et al., 2004) . scAAV vectors, which contain double-stranded genomes, and therefore bypass the requirement for viral second-strand DNA synthesis, lead to a significant increase in AAV-mediated transduction efficiency. The human CD40L is a 39-kDa type II membrane glycoprotein and its cDNA, which encodes a 261-amino-acids CD40L, is 786 bp (Hollenbaugh et al., 1992) . Based on our previous studies, the maximum size of scAAV is ∼ 3.3 kb. Apparently, it is suitable to use scAAV as a vector to deliver CD40L cDNA.
To this aim, the scAAV2/5 containing a GFP expression cassette was used to infect A549 cells. As expected, the transduction efficiency of scAAV2/5 in A549 cells was significant higher than that of conventional AAV2/5. The transduction efficiency of scAAV2/5 in A549 cells was increased 3-fold, compared to conventional AAV2/5 ( Figs. 2A and B) .
However, more effort to improve recombinant AAV (rAAV) vector-mediated gene transfer and transgene expression is still needed. Earlier studies suggested that AAV transduction could be enhanced by gamma-irradiation, exposure to genotoxic stress, and various chemotherapeutic agents (Kanazawa et al., 2001; Zhao et al., 2006) . Carboplatin is a chemotherapeutic agent, which is used frequently in lung carcinoma, however, the potential effect on AAV transduction efficiency has not been reported.
Carboplatin enhances the AAV transduction in A549 cells
We next explored the potential effect of co-administration of the chemotherapeutic agent carboplatin on AAV-mediated transgene expression. To this end, A549 cells were pre-exposed to 10 μg/ml carboplatin for 5 h before scAAV2/5 infection. This concentration of carboplatin is similar to plasma peak levels observed in pharmacokinetic studies. As shown in Figs. 2C and D, A549 cells pretreated with the chemotherapeutic agent carboplatin markedly increased AAV transgene expression (∼ 8-fold), p b 0.001. These results suggest that the combination of conventional chemotherapy with gene therapy may enhance the transduction of the therapeutic gene and will be beneficial to eradicate lung cancer cells.
Transgene expression after transduction with scAAV2/5/CD40L in A549 cells Based on our above experiments, we delivered CD40L to target A549 cells using scAAV2/5 as a vector. A549 cells were mock (treated with serum-free media) or infected with scAAV2/ 5/CD40L with or without carboplatin treatment at an MOI of 10 4 particles/cell. CD40L transgene expression in A549 cells was analyzed 48 h after infection with scAAV2/5/CD40L by Western blot and fluorescence-activated cell sorting (FACS). As can be seen in Fig. 3A , with scAAV2/5/CD40L infection, CD40L protein was expressed in A549 cells; and the expression was enhanced by carboplatin pretreatment. As expected, the FACS data demonstrated the percentage of CD40L positive cells was ∼ 20% with scAAV2/5/CD40L infection. However, this increased to 60% with carboplatin pretreatment (Fig. 3B) . Carboplatin increased the CD40L transgene expression ∼ 3-fold, whereas it enhanced the GFP expression ∼ 8-fold. The difference is because the former measures the number of positive cells by FACS while the latter measures total expression fluorescence microscopy and ImageJ software.
Stimulation of DCs by co-cultivation with scAAV2/5/CD40L-transduced A549 cells
To demonstrate functional gene transfer and provide the basis for the development of an immunotherapeutic model system, the immunostimulatory capacity of lung cancer A549 cells expressing CD40L as a consequence of rAAV-mediated gene transfer was investigated after co-cultivation of these cells with DCs. In this experiment, A549 cells were also infected with scAAV2/5/ CD40L at an MOI of 10 4 particles/cell.
Immature DCs were generated from isolated peripheral blood mononuclear cells (PBMCs) as described by Banchereau using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4) as essential stimuli (Banchereau and Steinman, 1998) . Authenticity of the DCs was confirmed by their typical morphology and flow cytometric assessment of upregulated cell surface determinants CD1a, CD80, CD86, MHC class I, and MHC class II, all markers of the conversion of monocyte precursors to immature DCs. Maturation to DCs that are able to activate CTLs is associated with up-regulation of antigen-presenting and co-stimulatory molecules including soluble cytokines, such as interleukin 12 (IL-12). Co-cultivation of transduced A549 cells with immature DCs resulted in their release of substantial IL-12. Therefore, we measured the levels of IL-12 in the supernatant of cell culture (Fig. 4) . Specificity of the immunostimulatory effect of CD40L was also confirmed by pre-incubation of scAAV2/5/CD40L-transduced cells with a monoclonal antibody binding to human CD40L. See Fig. 4 .
Suppression of s.c. tumor growth
The s.c. model was employed (see Materials and methods) to analyze the therapeutic potential of scAAV2/5-CD40L. Monitoring of tumor growth for 45 days revealed substantial growth reduction in the scAAV2/5-CD40L-injected tumors, but not in the scAAV2/5-GFP or PBS control groups. At the 45th day after inoculation of the tumor cells, the tumor sizes and weights were calculated. The tumor sizes and weights of the PBS-treated group and the scAAV2/5-GFP control group were 0.76 ± 0.10 cm 3 and 1.04 ± 0.15 g and 0.81 ± 0.14 cm 3 and 1.09 ± 0.20 g, respectively. Compared with these control groups, the tumor sizes and weights of the scAAV2/5-CD40L-treated group showed a significant decrease of 0.26 ± 0.08 cm 3 and 0.35 ± 0.08 g, P b 0.001. There was no significant difference between PBS-treated group and scAAV2/5-GFP control group, P N 0.05. The inhibition rate in the scAAV2/5-CD40L group was 66.8 ± 4.9%. Evidence to support tumor cell apoptosis was also provided by terminal nucleotidyl transferase (TdT)-mediated nick end labeling assays, demonstrating significantly higher levels of apoptotic cell death in the scAAV2/5-CD40L group on day 45 days. The apoptotic index of scAAV2/5-CD40L group was significantly higher than the PBS-treated group (17.26 ± 2.50% vs. 6.32 ± 1.10%, p b 0.001), and there was no significant difference between the PBS-treated group and the scAAV2/ 5-GFP control group (6.50 ± 0.99%, p N 0.05).
Discussion
Transduction of a therapeutic transgene may induce a persistent immune response to molecular characteristics of the malignant phenotype. Expression of CD40L, a member of the tumor necrosis factor protein family, in tumor cells has been recognized as an effective strategy to evoke or enhance an antitumor immune responses (Kikuchi and Crystal, 1999) . DCs, which are able to cross-present tumor-derived antigens after uptake and processing, are considered the most important professional APCs of the primary route of T-cell stimulation. An optimal priming of tumor-specific CTLs requires the assistance of CD4 + T-cells (Bennett et al., 1998; Schoenberger et al., 1998 ) which seems to be dependent on the binding of CD40L to CD40. Expression of CD40L in tumors facilitated the interaction between DCs and the tumors, enhanced the maturation of DCs, induced secretion of cytokines, and consequently produced T-cell-dependent systemic immunity (Tada et al., 2003) .
The AAV vector is nonpathogenic, has minimal vectorrelated toxicity, and induces a low host of cellular immune response. Moreover, AAV2 vectors are currently in use in phase I/II clinical trials for gene therapy for cystic fibrosis, hemophilia B, α-1 anti-trypsin deficiency and neurological disorders (Aitken et al., 2001; Flotte et al., 2004; Kay et al., 2000; Manno et al., 2003; Wagner et al., 2002) . To achieve better efficacy of gene therapy for lung carcinoma, discovering the best serotype of AAV vectors for gene delivery in lung cancer cells is the first important step. For this purpose, we examined the transduction efficiency of different serotypes of AAV 2/1, 2/2, 2/ 5, 2/6, 2/7, 2/8, 2/9 and 2/10 vectors in the lung adenocarcinoma A549 cell line. These results document that AAV2/5 was the most robust to deliver the gene in A549 cells. However, the transduction efficiency of AAV2/5 is still low.
Previous studies have suggested that viral second-strand DNA synthesis is the rate-limiting step in AAV-mediated transgene expression (Ferrari et al., 1996; Fisher et al., 1996; Mah et al., 1998; Zhong et al., 2004) . The scAAV vectors, which bypass the requirement of viral second-strand DNA synthesis, can increase the AAV transduction efficiency (McCarty et al., 2001; Wang et al., 2003) . Our current study suggests that scAAV2/5 increased the transduction efficiency ∼ 3-fold, compared with conventional AAV2/5, even though this increase is still modest. Our results also indicated that AAV-mediated gene transfer into lung cancer cells can be tremendously enhanced by co-administration of carboplatin compounds used in cancer chemotherapy. These observations provide the basis for in vivo studies to confirm the positive effects of simultaneously administered chemotherapy on intratumoral gene transfer.
Furthermore, as an initial step to prove the feasibility of a concept of lung cancer treatment based on CD40L gene transfer with AAV vectors, lung cancer cells were transduced with scAAV/CD40L and co-incubated with human DCs that had been generated from PBMCs. Remarkably, substantial activation of DCs, measured by IL-12 release, was achieved even when low susceptibility of A549 lung cancer cell lines to AAV-mediated transduction resulted in small fractions of transgene-expressing cells. That IL-12 secretion could be blocked with a monoclonal antibody binding to CD40L was indicative of a highly specific effect. These data support a possible mechanism of the antitumor responses: Tumor cells expressing CD40 can transcribe DCsderived cytokine genes by the expressed CD40L (Wada et al., 2004) .
Intratumoral transfer of CD40L-encoding DNA is considered a promising strategy to achieve prolonged activation of DCs in vivo leading to stronger immune responses by triggering CD8 + T-cells. Immune stimulation with DCs-based vaccines on the other hand apparently can not give rise to a long-lasting state of DCs activation with prolonged stimulation of T cells by secreted cytokines (Langenkamp et al., 2000) . For intratumoral gene transfer in different murine cancer model systems, adenoviral vectors have successfully been used to express CD40L (Kikuchi and Crystal, 1999; Loskog et al., 2004) . AAV-derived vectors are an attractive alternative to adenoviral systems in view of the fact that prolonged transgene expression can be achieved without induction of inflammation or an anti-AAV immune response. The capacity of the derived CD40L transgenic tumor cells to stimulate co-cultivated DCs was indicated by a substantial release of IL-12. The possible mechanism in part responsible for the observed effects of scAAV2/5-CD40L on the implanted tumor growth and apoptosis may be that local expression of CD40L on tumor cells via an amplicon vector would activate recruited DCs. These results underline the potential of rAAVbased gene therapy of lung cancer and provide a solid basis for future clinical trials. However, parallel to the generation of tumor-specific AAV derivatives, intratumoral AAV-mediated CD40L gene transfer needs to be further studied in vivo to provide a solid basis for future clinical studies.
In summary, we have shown that so far AAV2/5 is the most efficient serotype vector for gene transduction in A549 cells. The efficiency of scAAV2/5-mediated gene transfer into A549 lung cancer cells is significantly higher than that of conventional AAV, and it can be further enhanced by co-administration of a chemotherapeutic agent. As a basis for future immunotherapeutic approaches including intratumoral transfer of stimulating factors, we also confirmed that lung cancer cells infected with a CD40L-encoding AAV can activate human DCs to secrete IL-12, and intratumoral administration of scAAV2/5-CD40L can inhibit the growth of implanted tumor and increase tumor cells apoptosis.
Materials and methods
Cells
The human lung adenocarcinoma cell line A549 was maintained at 37°C in a 5% CO 2 atmosphere in RPMI 1640 media supplemented with 10% fetal bovine serum and 1% (by volume) 100× stock solution of antibiotics (10,000 U of penicillin plus 10,000 μg of streptomycin).
To generate human DCs, PBMCs were isolated by centrifugation in a Ficoll density gradient and enrichment of monocytes was achieved by an adherence step as described previously (Koppold et al., 2005) . To generate DCs, the isolated monocytes were transferred to 6-well plates and cultured in RPMI 1640 supplemented with 10% heat-inactivated human AB serum, penicillin/streptomycin, and 100 U/ml heparin. After 8 h, recombinant human GM-CSF and IL-4 were added. These factors were renewed after 3 days. Monocytes and DCs were immunophenotyped with a set of monoclonal antibodies binding to CD1a, CD14, CD86, CD206, MHC-I and MHC-II. These antibodies were conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or phycoerythrin cyanine 5 (PE-Cy5) and were from BD Pharmigen company.
Animals
Female 5-to 6-week-old BALB/c nude mice were housed at a constant temperature and supplied with laboratory chow and water on a 12-h dark/light cycle in specific pathogen-free conditions.
Construction, production and measurement of titers of the rAAV vectors
Standard cloning techniques were used for constructing all recombinant plasmids. To construct plasmids pCMV-CD40L, which are conventional AAV vectors containing human CD40L cDNA, pAAV-hrGFP was digested with Sac I/Rsr I and ligated with the CD40L cDNA fragment. To construct plasmids pdsAAV-CMV-CD40L, which are scAAV vectors containing human CD40L cDNA, pJW3 was digested with Sac I and ligated with the CD40L cDNA fragment. All vectors and inserts were treated with the Klenow fragment of Italicize Escherichia coli DNA polymerase I and then bluntend-ligated. rAAV vectors were produced using the calcium phosphate triple-plasmid transfection protocol (Zhao et al., 2006) . All recombinant vectors were purified using the CsCl density gradient method. The titers of DNA-containing viral particles were determined by quantitative DNA slot blot.
rAAV vector-mediated transduction assays Approximately 1.5 × 10 5 A549 cells were plated in each well in 12-well plates and incubated at 37°C for 18 h. Cells were washed once with serum-free media and then either mockinfected or infected with AAV vectors at a multiplicity of infection (MOI) of 1 × 10 4 particles/cell. 48 h post-infection, cells were observed under a Zeiss Axiovert 25 fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY). The viral transduction efficiency was measured by GFP imaging using images from three visual fields of mock-infected and vector-infected cells 48 h post-infection and analyzed quantitatively by ImageJ analysis software (NIH, Bethesda, MD). Transgene expression was assessed as total area of green fluorescence (pixel 2 ) per visual field (mean ± SD).
To evaluate the potential effect of the chemotherapeutic agent carboplatin on AAV transduction efficiency, A549 cells were plated and incubated 18 h, and before infection, the cells were treated with 10 μg/ml carboplatin for 5 h. After incubation of cells with carboplatin, cells were washed once with serum-free media and then infected with AAV vectors.
To determine AAV-mediated expression of the human CD40L, whole cell extracts (WCEs) were prepared (Zhao et al., 2006) . Total protein concentrations were determined using the Bio-Rad protein assay kit, and 40 μg of protein was separated by SDS-polyacrylamide gel electrophoresis on a 10% polyacrylamide gel. After transfer to an Immobilon-P membrane (Millipore, Bedford, MA), the membrane was blocked at 25°C for 1 h with 5% nonfat dry milk in 1× Tris-buffered saline (TBS), and 0.05% Tween 20, then incubated with a 1:500 dilution of anti-CD40L antibody for 1 h at 25°C. Following incubation with 1:5000 dilution of horseradish peroxidase-coupled antirabbit IgG antibody for 1 h at 25°C, protein bands were visualized with the ECL-Plus chemiluminescence detection kit (Amersham Biosciences, Piscataway, NJ). Cells were also harvested 48 h post-infection and analyzed by FACS. Briefly, cells were washed twice with washing buffer (PBS containing 10% fetal bovine serum). For FACS, cells were resuspended in 80 μl washing buffer, then 0.5-1.0 μg phycoerythrin (PE)-conjugated monoclonal antibody specific for CD40L (BD Pharmingen) was added and incubated for 20 min. Then cells were washed twice with 2-ml washing buffer and resuspended in 0.5 ml PBS for analysis by FACS. PE-labeled hamster IgG3 isotype was used as control antibody.
Activation of DCs co-cultivation with CD40L transgenic A549 cells
The potential of CD40L-transgenic A549 cells to activate DCs was analyzed by co-incubation of similar numbers of both cell types for 48 h. Secretion of IL-12 was measured with an immunoassay (BD Pharmingen) specific for IL-12. To specifically block activation of DCs mediated by transgenic CD40L, we used a monoclonal antibody binding to human CD40L.
S.c. tumor xenografts and assessment of growth
A549 cells (1 × 10 7 ) were administered in the s.c. tissue of the right flank of BALB/c nude mice. Tumor growth was monitored regularly and volume (V) was calculated using the formula V = 1/2 × length × (width) 2 . When tumor size reached ∼50 mm 3 (about 14 days post-inoculation), animals were randomized into three groups (in each group, n = 5) and vectors were administered by intratumoral injection. Groups 1 and 2 received 2 × 10 11 particles scAAV2/5-CD40L or scAAV2/5-GFP, respectively; and group 3 mice received PBS as control. Mice were sacrificed 45 days after tumor cell implantation. The inhibitory rate (IR) was calculated using the formula, IR = (1 − mean tumor weight of the treated group / mean tumor weight of the control group) × 100%. Apoptosis was measured by TUNEL, and the apoptotic index (AI) was calculated using the formula, AI = number of the apoptotic cells / number of the total cells which will be observed, and the total cells which were observed was not less than 1000 cells.
Statistical analysis
All data are reported as mean ± standard error. One way ANOVA was used to evaluate statistical significance by SigmaStat software. P values were considered to be statistically significant when b0.05.
